Basi Scientifiche per Linee Guida

11.0 BIBLIOGRAFIA (prima parte)

EPIDEMIOLOGIA E FATTORI DI RISCHIO

Adami H-O, Hsing AW, McLaughlin JK, et al. Alcoholism and liver cirrhosis in the etiology of primary liver cancer. Int J Cancer 1992; 51:898-902

Beasley RP, Hwang L-Y, Lin C-C et al. Hepatocellular carcinoma and hepatitits B virus. Lancet 1981; 2:1129-1133

Bosetti C, La Vecchia C, Lipworth L, McLaughlin K. Occupational exposure to vinyl chloride and cancer risk: A review of the epidemiologic literature. Eur J Cancer Prev 2003; 12:427-430

Chen ZM, Liu BQ, Boreham J, Wu YP, Chen JS, Peto R. Smoking and liver cancer in China; case-control comparison of 36,000 liver cancer deaths vs. 17,000 cirrhosis deaths. Int J Cancer 2003; 107:106-112

Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-680

Donato F, Boffetta P, Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75:347-354

Hsing AW, Guo W, Chen J, et al. Correlates of liver cancer mortality in China. Int J Epidemiol 1991; 20:54-59

Kuper HE, Tzonou A, Kaklamani E, Hadziyannis S, Tasopoulos N, Lagiou P, Trichopoulos D, Stuver S. Hepatitis B and C viruses in theetiology of hepatocellular carcinoma; a study in Greece using thirdgeneration assays. Cancer Causes Control 2000; 11:171-175

La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000; 36:909-915

La Vecchia C, Negri E, Cavalieri D’Oro L, Franceschi S. Liver cirrhosis and the risk of primary liver cancer. Eur J Cancer Prev 1998; 7:315-320

La Vecchia C, Negri E, Decarli A, et al. Risk factors for hepatocellular carcinoma in Northern Italy. Int J Cancer 1988; 42:872-876

La Vecchia C, Negri E, Pelucchi C. The rise and fall in primary liver cancer mortality in Italy. Digestive Liver Dis 2002; 34:169-171

Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer 2004; 110:155-169

Lingao AL, Domingo EO, Nishioka K. Hepatitis B virus profile of hepatocellular carcinoma in the Philippines. Cancer 1981; 48:1590-1595

Linsell CA, Peers FG. Field studies on liver cell cancer. In: Origins of Human Cancer, Hiatt HH, Watson JD, Winsten JA (eds.). Book A. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1977; pp 549-556

McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94:290-296

Nomura A, Stemmermann GN, Wasnich RD. Presence of hepatitis B surface antigen before primary hepatocellular carcinoma. JAMA 1982; 247:2247-2249

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156

Schreiber WM, Kato H, Robertson JD. Primary carcinoma of the liver in Hiroshima and Nagasaki, Japan. Cancer 1970; 26:69-75

Simonetti RG, Camma C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxi A, Ciccaglione A, Giuseppetti R, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992; 116:97-102

Stroffolini T, Chiaramonte M, Tiribelli C et al. Hepatitis C virus infection, HBsAg carrier state and hepatocellular carcinoma: Relative risk and population attributable risk from a case-control study in Italy. J Hepatol 1992; 16:360-363

Tabor E, Kobayashi K. Hepatitis C virus, a causative infectious agent of non-A, non-B hepatitis: Prevalence and structure: Summary of a Conference on Hepatitis C Virus as a Cause of Hepatocellular Carcinoma. J Natl Cancer I 1992; 84:86-90

Trichopoulos D, Day NE, Kaklamani E et al. Hepatitits B virus, tobacco smoking and ethanol consumption in the etiology of hepatocellular carcinoma. Int J Cancer 1987; 39:45-49

Trichopoulos D, MacMahon B, Sparros L et al. Smoking and hepatitis B-negative primary hepatocellular carcinoma. J Natl Cancer I 1980; 65:111-114

Trichopoulos D, Tabor E, Gerety RJ et al. Hepatitis B ad primary hepatocellular carcinoma in a European population. Lancet 1978; 2:1217-1219

Tsukuma H, Hiyama T, Oshima A et al. A case-control study of hepatocellular carcinoma in Osaka, Japan. Int J Cancer 1990; 45:213-236

WHO, IARC. Hormonal contraception and Post-menopausal Hormonal Therapy. IARC Monogr Eval Carcinog Risks Hum 1999; 72

Yu H, Harris RE, Kabat GC et al. Cigarette smoking, alcohol consumption and primary liver cancer: A case-control study in the USA. Int J Cancer 1988; 42:325-328

Yu MC, Mack T, Hanisch R et al. Hepatitis, alcohol consumption, cigarette smoking, and hepatocellular carcinoma in Los Angeles. Cancer Res 1983; 43:6077-6079

Zavitsanos X, Hatzakis A, Kaklamani E et al. Association between hepatitis C virus and hepatocellular carcinoma using assays based on structural and nonstructural hepatitits C virus peptides. Cancer Res 1992; 52: 5364-5367


PATOGENESI E BASI GENETICHE

Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22:5093-5107

Borzio M, Fargion S, Borzio F, Fracanzani AL, Croce AM, Stroffolini T, Oldani S, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39:208-214

Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5:215-219

Buendia MA. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med Pediatr Oncol 2002; 39:530-535

Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C, Levrero M. The hepatitis B virus X gene induces p53-mediated programmed cell death. Proc Natl Acad Sci USA 1997; 94:8162-8167

Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003; 60:145-150

Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21:2593-2604

Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 2001; 20:2606-2610

Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70

Kim JW, Wang XW. Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis 2003; 24:363-369

Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87:159-170

Koike K. Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. J Gastroenterol 2002; 37(Suppl 13):55-64

Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120:1763-1773

Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang JY, Melino G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci 2000; 113:1661-1670

Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M. Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003; 26:142-147

Paradis V, Bieche I, Dargere D, Laurendeau I, Laurent C, Bioulac Sage P, Degott C et al. Molecular profiling of hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR approach: determination of a molecular diagnostic index. Am J Pathol 2003; 163:733-741

Park YN, Chae KJ, Kim YB, Park C, Theise N. Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer 2001; 92:2733-2738

Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D, et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003; 22:3911-3916

Roskams TA, Libbrecht L, Desmet VJ. Progenitor cells in diseased human liver. Semin Liver Dis 2003; 23:385-396

Sell S. Cellular origin of hepatocellular carcinomas. Semin Cell Dev Biol 2002; 13:419-424

Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18:4848-4859

Smith MW, Yue ZN, Geiss GK, Sadovnikova NY, Carter VS, Boix L, Lazaro CA, et al. Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res 2003; 63:859-864

Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003; 21:201-216

Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Putzer BM. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10:626-633

Theise ND, Park YN, Kojiro M. Dysplastic nodules and hepatocarcinogenesis. Clin Liver Dis 2002; 6:497-512

Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, et al. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002; 181-182:43-47

Waris G, Siddiqui A. Regulatory mechanisms of viral hepatitis B and C. J Biosci 2003; 28:311-321


PREVENZIONE

Aufiro B, Schneider RJ. The hepatitis B virus X gene product transativates both RNA polymerase II and III promoters. EMBO J 1990; 9:497-504

Bonino F, Oliveri F, Colombatto P, Coco B, Mura D, Realdi G, Brunetto MR. Treatment of patients with chronic hepatitis C and cirrhosis. J Hepatology 1999; 31(S1):197-200

Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA in human hepatocellular carcinoma. Nature 1980; 286:533-535

Bréchot C, Thiers V, Kremsdorf D, Bertrand N, Pol S, Paterlini-Bréchot P. Persistent Hepatitis B Virus Infection in Subjects Whithout Hepatitis B Virus Surface Antigen: Clinically Significant or Purely "Occult"? Hepatology 2001; 34(1):194-203

Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36:263-70

Brunetto MR, Oliveri F, Koehler M, Zahm F, Bonino F. and the international HHC Study Group Effect of alpha IFN in progression of cirrhosis to HHC: a prospective cohort study. Lancet 1998; 351:1535-39

Cammà C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34:593-602

Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336:1855-1859

Chiba T, Matsuzaki Y, Abei M, Shoda J, Tanaka N, Osuga T et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 1996; 91(6):1195-1203

Di Marco V, Marzano A, Lampertico P et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to Lamivudine. Hepatology 2004; 40:883-891

Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Longterm outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26(5):1338-42

Fausto N. Growth factors in liver development, regeneration and carcinogenesis. Prog Growth Factor Res 1991; 3:219-234

Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Naito M, Masuzawa M, Yoshihara H, Shimizu Y, Fusamoto H, Kamada T. Long term biochemical and virological response to natural interferon-alpha in patients with chronic hepatitis C. Dig Dis Sci 1996; 41:1001-1007

Hsu T, Moroy T, Etiemble J, Louise A, Trepo C, Tiollais P, Buendia MA. Activaton of c-myc by woodchuck hepatitis virus infection in hepatocellular carcinoma. Cell 1988; 55:627-635

Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS2/s region of integrated hepatitis B virus DNA encodes a transcriptional activator. Nature 1990; 343:457-460

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Hamba H, Shuto T, Yamamoto T, Ikebe T, Kinoshita H. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999; 86(5):793-798

Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531

Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4(9):1065-1067

Nagasue N, Ito A, Yukaya H, Ogawa Y. Estrogen receptors in hepatocellular carcinoma. Cancer 1986; 57:87-91

Ohnishi S, Murakami T, Moriyama T, Mitamura K, Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding liver tissue. Hepatology 1986; 6:440-443

Oliveri F, Brunetto MR, Actis GC, Bonino F. Pathobiology of chronic hepatitis virus infection and hepatocellular carcinoma (HCC). Ital J Gastroenterol 1991; 23:498-502

Oliveri F, Colombatto P, Derenzini M, Trerè D, Papotti M, David E, Negro F, Bellati G, Ideo G, D’Acquino M, Michieletto L, Verme G, Bonino F, Brunetto MR. Hepatocellular Carcinoma: Pathogenetic implications of hepatitis Delta Virus. Prog Clin Biol Res 1993; 382:165-170

Papatheodoridis GV, Papadimitropoulos V, Hadzyiannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a metaanalysis. Aliment Pharmacol Ther 2001; 15:689-698

Paterlini P, Bréchot C. The detection of hepatitis B virus (HBV) in HBsAg negative individuals with primary liver cancer. Dig Dis Sci 1991; 36(8):1122-9

Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Crax A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126:102-10

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, de Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126:1005-14

Villa E, Dugani A, Moles A, Camellini L, Grottola A, Buttafuoco P, Merighi A, Ferretti I, Esposito P, Miglioli L, Bagni A, Troisi R, De Hemptinne B, Praet M, Callea F, Manenti F. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 1998; 27(4):983-988

Wang JS, Shen X, He X, et al. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People’s Republic of China. J Natl Cancer Inst 1999; 91:347-354


PROTOCOLLI DI SORVEGLIANZA

Bolondi L, Benzi G, Santi V, Gaiani S, Li Bassi SL, Zironi G, et al. Links relationship between alpha-fetoprotein serum levels, tumour volume and growth rate of hepatocellular carcinoma in a western population. Ital J Gastroenterol 1990; 22:190-4

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48:251-59

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical menagement of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421-30

Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, Bru C, Bruix C for the Barcelona Clinic Liver Cancer (BCLC) Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: An explant correlation. Hepatology 2003; 38:1034-42

Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, Siena DA, et al. Diagnosis of liver nodules observed in chronic liver disease patients during ultrasound screening for early detection of hepatocellular carcinoma. Am J Gastroenterol 2002; 97:1-9

Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999; 94:2224-9

Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27(1):273-8

Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M et al. A prospective study of the development of hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325:675-80

Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child’A cirrhosis: a 8-years prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 6:1029-34

El Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35(suppl 2):S72-8

Everson GT. Increasing incidence and pretransplantation screening of hepatocellular carcinoma. Liver Transpl 2000; 6(Suppl 2):S2-10

Freeman RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E et al. The new allocation system: moving towards evidence-based transplantation policy. Liver Transplant 2002; 8:851-8

Gaiani S, Piscaglia F, Celli N, Cecilioni L, Masi L, Rasciti L et al. Perfusional angiosonography (CnTi Esaote) with 2nd generation ultrasound contrast agent in the chracterization of nodules in cirrhosis. Hepatology 2002; 36(suppl):2133

Gambarin-Gelwan M, Wolf D, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000; 95:1535-8

Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, et al. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36(Suppl):S84-92

Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002; 36:1349-54

Miller WJ, Baron RL, Dodd GD, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients. Radiology 1994; 193:645-50

Oka H, Kurioka N, Kim K et al. Prospective study of early detection of hapatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12:680-7

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, de Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126:1005-14

Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, Mannucci PM, and the Study Group of the Association of Italian Hemophilia Centers. Six-month versus 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102:78-82

Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101:422-34

Solmi L, Primerano AM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 1996; 91:1189-94

Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US and PET. Radiology 2003; 226:533-542

Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnu L, Zoli M et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97:734-44

Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-801

Velazquez RF, Rodriguez M, Navascues CA, Linares A, Perez R, Sotorrios NG et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37:520-7

Yang B, Zhang B, Xu Y, Wang W, Shen Y, Whang A, Xu Z. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997; 123:357-60

Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394-1404

Yuen MF, Cheng CC, Lauder IJ, et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31:330-5

Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of Hepatocellular carcinoma. Cancer 1996; 78:977-85


DIAGNOSI

Biomarcatori circolanti
Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98(3):679-90

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-30

Chang YC, Ho CL, Chen HH, Chang TT, Lai WW, Dai YC, Lee WY, Chow NH. Molecular diagnosis of primary liver cancer by microsatellite DNA analysis in the serum. Brit J Cancer 2002; 87(12):1449-53

Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS, El-Kamary SS, Bass EB. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36(5 Suppl 1):S84-92

Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139(1):46-50

Khien VV, Mao HV, Chinh TT, Ha PT, Bang MH, Lac BV, Hop TV, Tuan NA, Don LV, Taketa K, Satomura S. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 2001; 16(2):105-11

Liu Y, Wu MC, Qian GX, Zhang BH. Detection of circulating hepatocellular carcinoma cells in peripheral venous blood by reverse transcription-polymerase chain reaction. Hepatob Pancreat Dis In 2002; 1:72-6

Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003; 37(5):1114-21

Mizejewski GJ. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv 2003; 58:804-26

Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306(1):16-25

Nguyen MH, Garcia RT, Simpson PW, Wright TL, Keeffe EB. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology 2002; 36(2):410-7

Nunez EA. Biological role of alpha-fetoprotein in the endocrinological field: data and hypothesis. Tumour Biol 1994; 15:63-72

Poon TC, Mok TS, Chan AT, Chan CM, Leong V, Tsui SH, Leung TW, Wong HT, Ho SK, Johnson PJ. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin Chem 2002; 48(7):1021-7

Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52:1-8

Sugimoto H, Takeda S, Inoue S, Kaneko T, Watanabe K, Nakao A. Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma. Liver Int 2003; 23(1):38-44

Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S, Makuuchi M. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 2003; 22(5):969-75

Tomasi TB. Structure and function of alpha-fetoprotein. Ann Rev Med 1977; 28:453-65

Weitz IC, Liebman HA. Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology 1993; 18:990-7

Witzigmann H, Geissler F, Benedix F, Thiery J, Uhlmann D, Tannapfel A, Wittekind C, Hauss J. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein messenger RNA in patients with hepatocellular carcinoma. Surgery 2002; 131(1):34-43

Wun YT, Dickinson JA. Alpha-fetoprotein and/or liver ultrasonography for liver cancer screening in patients with chronic hepatitis B. Cochrane Database Syst Rev 2003; (2):CD002799

Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, Murota M, Kita Y, Watanabe S, Kuriyama S. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002; 20(2):305-9

Yuen MF, Lai CL. Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. Ann Oncol 2003; 14(10):1463-7


Tecniche d’immagine: ecografia
Albrecht T, Blomley M, Bolondi L, Claudon M, Correas JM, Cosgrove D, Greiner L, Jager K, de Jong N, Leen E, Lencioni R, Lindsell D, Martegani A, Solbiati L, Thorelius L, Tranquart F, Weskott HP, Whittingam T; EFSUMB Study Group. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med 2004; 25:249-256

Bennett GL, Krinsky GA, Abitbol RJ, Kim SY, Theise ND, Teperman LW. Sonographic detection of hepatocellular carcinoma and dysplastic nodules in cirrhosis: correlation of pretransplantation sonography and liver explant pathology in 200 patients. AJR Am J Roentgenol 2002; 179:75-80

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430

Catalano O, Lobianco R, Cusati B, Siani A. Hepatocellular carcinoma: spectrum of contrast-enhanced gray-scale harmonic sonography findings. Abdom Imaging 2004; 29:341-347

Colombo M, Sangiovanni A. The European approach to hepatocellular carcinoma. Hepatogastroenterology 2002; 49:12-16

Dodd GD 3rd, Miller WJ, Baron RL, Skolnick ML, Campbell WL. Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique. AJR Am J Roentgenol 1992; 159:727-733

Gaiani S, Celli N, Piscaglia F, Cecilioni L, Losinno F, Giangregorio F, Mancini M, Pini P, Fornari F, Bolondi L. Usefulness of contrastenhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol 2004; 41:421-426

Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001; 20:99-104

Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrastspecific imaging: back to gray scale in ultrasound. Eur Radiol 2002; 12:151-165

Lencioni R, Cioni D, Crocetti L, Donati F, Franchini C, Giusti S, Bartolozzi C. Ultrasound imaging of focal liver lesions with a second-generation contrast agent. Acad Radiol 2002; 9 Suppl 2:S371-374

Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, Desmet V, Roskams T. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 2002; 8:749-76

Liu WC, Lim JH, Park CK, Kim MJ, Kim SH, Lee SJ, Lee WJ, Lim HK. Poor sensitivity of sonography in detection of hepatocellular carcinoma in advanced liver cirrhosis: accuracy of pretransplantation sonography in 118 patients. Eur Radiol 2003; 13:1693-1698

Nicolau C, Catala V, Vilana R, Gilabert R, Bianchi L, Sole M, Pages M, Bru C. Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent: correlation with cellular differentiation. Eur Radiol 2004; 14:1092-1099

Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L, Pozzi-Mucelli R. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004; 232:420-430

Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G, Henry L, Berger F, Bizollon T, Gaudin JL, Ducerf C. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25:327-336

Shapiro RS, Katz R, Mendelson DS, Halton KP, Schwartz ME, Miller CM. Detection of hepatocellular carcinoma in cirrhotic patients: sensitivity of CT and ultrasonography. J Ultrasound Med 1996; 15:497-502

Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, Irie H, Aibe H, Shimada M, Masuda K. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol 2002; 178:885-897

Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226:533-542

Tecniche d’immagine: TC ed RM
Barthia B, Ward J, Guthrie JA, Robinson PJ. Hepatocellular carcinoma in cirrhotic livers: double-contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am J Roentgenol 2003; 180:577-84

Bartolozzi C, Donati F, Cioni D, Crocetti L, Lencioni R. MnDPDPenhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. Eur Radiol 2000; 10:1697-1702

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-30

Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Sole M, Sanchez M, Bru C, Bruix J; Barcelona Clinic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:1034-42

Choi D, Kim SH, Lim JH, Cho JM, Lee WJ, Lee SJ, Lim HK. Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 2001; 25:777-85

Colombo M, Sangiovanni A. The European approach to hepatocellular carcinoma. Hepatogastroenterology 2002; 49:12-6

de Lédinghen V, Laharie D, Lecesne R, Le Bail B, Winnock M, Bernard PH, Saric J, Couzigou P, Balabaud C, Bioulac-Sage P, Drouillard J. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002; 14:159-165

Kang BK, Lim JH, Kim SH, Choi D, Lim HK, Lee WJ, Lee SJ. Preoperative depiction of hepatocellular carcinoma: ferumoxidesenhanced MR imaging versus triple-phase helical CT. Radiology 2003; 226:79-85

Kato H, Kanematsu M, Kondo H, Goshima S, Matsuo M, Hoshi H, Moriyama N. Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity. J Magn Reson Imaging 2004; 19:76-81

Kim T, Murakami T, Hori M, Takamura M, Takahashi S, Okada A, Kawata S et al. Small hypervascular hepatocellular carcinoma revealed by double arterial phase CT performed with single breathhold scanning and automatic bolus tracking. AJR Am J Roentgenol 2002; 178:899-904

Krinsky GA, Lee VS, Theise ND, Weinreb JC, Rofsky NM, Diflo T, Teperman LW. Hepatocellular carcinoma and dysplastic nodules in patients with cirrhosis: prospective diagnosis with MR imaging and explantation correlation. Radiology 2001; 219:445-54

Lee KH, O’Malley ME, Haider MA, Hanbidge A. Triple-phase MDCT of hepatocellular carcinoma. AJR Am J Roentgenol 2004; 182:643-9

Lencioni R, Cioni D, Crocetti L, Della Pina C, Bartolozzi C. Magnetic resonance imaging of liver tumors. J Hepatol 2004; 40:162-71

Lim JH, Choi D, Cho SK, Kim SH, Lee WJ, Lim HK, Park CK, et al. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 2001; 220:669-76

Lim JH, Choi D, Kim SH, Lee SJ, Lee WJ, Lim HK, Kim S. Detection of hepatocellular carcinoma: value of adding delayed phase imaging to dual-phase helical CT. AJR Am J Roentgenol. 2002; 179:67-73

Lim JH, Kim CK, Lee WJ, Park CK, Koh KC, Paik SW, Joh JW. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic livers: accuracy of helical CT in transplant patients. AJR Am J Roentgenol 2000; 175:693-8

Murakami T, Kim T, Kawata S, Kanematsu M, Federle MP, Hori M, Okada A, Kumano S, Sugihara E, Tomoda K, Nakamura H. Evaluation of optimal timing of arterial phase imaging for the detection of hypervascular hepatocellular carcinoma by using triple arterial phase imaging with multidetector-row helical computed tomography. Invest Radiol 2003; 38:497-503

Noguchi Y, Murakami T, Kim T, Hori M, Osuga K, Kawata S, Kumano S, Okada A, Sugiura T, Nakamura H. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180:455-60

Pauleit D, Textor J, Bachmann R, Conrad R, Flacke S, Layer G, Kreft B, et al. Hepatocellular carcinoma: detection with gadoliniumand ferumoxides-enhanced MR imaging of the liver. Radiology 2002; 222:73-80

Petersein J, Spinazzi A, Giovagnoni A, Soyer P, Terrier F, Lencioni R, Bartolozzi C, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology 2000; 215:727-36

Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G, Henry L, et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001; 25:327-36

Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, Irie H, Aibe H, Shimada M, Masuda K. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol 2002; 178:885-97

Teefey SA, Hildeboldt CC, Dehdashti F, Siegel BA, Peters MG, Heiken JP, Brown JJ, McFarland EG, Middleton WD, Balfe DM, Ritter JH. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US, and PET. Radiology 2003; 226:533-42

Valls C, Cos M, Figueras J, Andia E, Ramos E, Sanchez A, Serrano T, Torras J. Pretransplantation diagnosis and staging of hepatocellular carcinoma in patients with cirrhosis: value of dualphase helical CT. AJR Am J Roentgenol 2004; 182:1011-7

Biopsia epatica percutanea
Bret PM, Labadie M, Bretagnolle M, Paliard P, Fond A, Valette PJ. Hepatocellular carcinoma: diagnosis by percutaneous fine needle biopsy. Gastrointest Radiol 1988; 13(3):253-5

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35(3):421-30

Buscarini L, Fornari F, Bolondi L, Colombo P, Livraghi T, Magnolfi F, Rapaccini GL, Salmi A. Ultrasound-guided fine-needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. A retrospective study on 2091 biopsies. J Hepatol 1990; 11(3):344-8

Caturelli E, Giacobbe A, Facciorusso D, Bisceglia M, Villani MR, Siena DA, Fusilli S, Squillante MM, Andriulli A. Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. Am J Gastroenterol 1996; 91(7):1318-21

Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, Moutardier V, Farges O, Valla D. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001; 35(2):254-8

Fornari F, Civardi G, Cavanna L, Di Stasi M, Rossi S, Sbolli G, Buscarini L. Complications of ultrasonically guided fine-needle abdominal biopsy. Results of a multicenter Italian study and review of the literature. The Cooperative Italian Study Group. Scand J Gastroenterol 1989; 24(8):949-55

Fornari F, Filice C, Rapaccini GL, Caturelli E, Cavanna L, Civardi G, Di Stasi M, Buscarini E, Buscarini L. Small (< or = 3 cm) hepatic lesions. Results of sonographically guided fine-needle biopsy in 385 patients. Dig Dis Sci 1994; 39(10):2267-75

Huang GT, Sheu JC, Yang PM, Lee HS, Wang TH, Chen DS. Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma - a study based on 420 patients. J Hepatol 1996; 25(3):334-8

Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle-tract implantation in hepatocellular carcinoma: frequency and CT findings after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000 May-Jun; 25(3):246-50

Kondo F, Wada K, Nagato Y, Nakajima T, Kondo Y, Hirooka N, Ebara M, Ohto M, Okuda K. Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 1989; 9(5):751-5

Livraghi T, Damascelli B, Lombardi C, Spagnoli I. Risk in fineneedle abdominal biopsy. J Clin Ultrasound 1983; 11(2):77-81

Longchampt E, Patriarche C, Fabre M. Accuracy of cytology vs. microbiopsy for the diagnosis of well-differentiated hepatocellular carcinoma and macroregenerative nodule. Definition of standardized criteria from a study of 100 cases. Acta Cytol 2000; 44(4):515-23

Sangalli G, Livraghi T, Giordano F. Fine needle biopsy of hepatocellular carcinoma: improvement in diagnosis by microhistology. Gastroenterology 1989; 96(2 Pt 1):524-6

Sbolli G, Fornari F, Civardi G, Di Stasi M, Cavanna L, Buscarini E, Buscarini L. Role of ultrasound guided fine needle aspiration biopsy in the diagnosis of hepatocellular carcinoma. Gut 1990; 31(11):1303-5

Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Review Radiology 1991; 178(1):253-8

Diagnosi istologica e citologica
Borzio M, Fargion S, Borzio F, et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. J Hepatol 2003; 39:208-214

Craig JR, Peters RL, and Edmondson HA. Tumors of the liver and intrahepatic bile ducts. In: Atlas of Tumor Pathology, Washington DC, Armed Forces Institute of Pathology (AFIP) 1988, pp. 48-169

D’Errico A, Baccarini P, Fiorentino M et al. Histogenesis of primary liver carcinomas: strengths and weaknesses of cytokeratin profile and albumin mRNA detection. Hum Pathol 1996; 27:599-604

Furuya K, Nakamura M, Yamamoto Y, Togei K, Otsuka H. Macroregenerative nodule of the liver. A clinicopathologic study of 345 autopsy cases of chronic liver disease. Cancer 1988; 61(1):99-105

Grigioni WF, D’Errico A, Bacci F, Carella R, Mancini AM. Small liver masses in cirrhotic patients. A clue for the morphogenesis of human hepatocellular carcinoma. Acta Pathol Jpn 1998, 39(8):520-527

Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. In: Viruses and Liver Cancer: perspectives in medical virology; Tabor E (Ed). Elsevier, Amsterdam; 2002, 113-122

Kondo F, Wada K, Nagato Y et al. Biopsy diagnosis of welldifferentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 1989; 9(5):751-5

Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699

Roncalli M, Roz E, Coggi G, et al. The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver: implications and classification. Hepatology 1999; 30:1174-1178

Scott FR, El-Refaie A, More L, et al. Hepatocellular carcinoma arising in adenoma: value of Qbend 10 immunostaining in diagnosis of liver cell carcinoma. Histopathology 1996; 28:472-474

Sell S. Cellular origin of hepatocellular carcinomas. Seminars in Cell & Developmental biology 2002; 13:419-424

Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellularcholangiocarcinoma. Am J Surg Pathol 2002; 26(8):989-997

Predittori istologici e molecolari
Adachi E, Maeda T, Matsumata T et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995; 108:768-75

Altimari A, Fiorentino M, Gabusi E, et al. Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primari liver tumours. Dig Liver Dis 2003; 35:332-338

El-Assal ON, Yamanoi A, Soda Y et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998; 27:1554-1562

Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000; 32:78-84

Endo K, Ueda T, Ueyama J et al. Immunoreactive E-cadherin, α-catenin, β-catenin, and γ-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients’survival. Hum Pathol 2000; 31:558-565

Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 2004; 17:1378-85

Fiorentino M, Altimari A, D’Errico A, et al. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma. Clin Cancer Res 2000; 6:3966-3972

Giannelli G, Bergamini C, Marinosci F et al. Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. Int J Cancer 2002; 97:425-31

Hsu HC, Jeng YM, Mao TL, et al. β-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B and with favourable prognosis. Am J Pathol 2000; 157:763-770

Huang GT, Lee HS, Chen C et al. Correlation of E-cadherin expression and recurrence of hepatocellular carcinoma. Hepato-Gastroenterology 1999; 46:1923-27

Ikeguci M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and survivin messanger RNA expression in hepatocellular carcinoma. Clin Cancer Res 2002; 8(10):3131-6

Inagawa S, Itabashi M, Adachi S et al. Expression and prognostic roles of β-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res 2002; 8:450-456

Ito T, Shiraki K, Sugimoto K, et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31:1080-5

Ito Y, Matsuura N, Sakon M et al. Both cell proliferation and apoptosis significantly predict shortened desease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81:747-751

Ito Y, Matsuura N, Sakon M, et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 indipendently predicts the recurrence. Hepatology 1999; 30:90-99

Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84:1377-1383

Ito Y, Takeda T, Sakon M, et al. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 2000; 59:68-74

Jiang YF, Yang ZH and Hu JQ. Recurrence or meastasis of HCC: predictors, early detection and experimental antiangiogenic therapy. World J Gastroenterol 2000, 6:61-65

Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion ang histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33(5):1080-1086

Kawate S, Fukusato T, Ohwada S et al. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 1999; 57:157-163

Kobayashi T, Kubota K, Takayama T and Makuuchi M. Telomerase activity as a predictive marker for recurrence of hepatocellular carcinoma after hepatectomy. Am J Surg 2001; 181:284-8

Maatta M, Soini Y, Liakka A and Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res 2000; 6:2726-34

Mao TL, Chu JS, Jeng YM et al. Expression of mutant nuclear β-catenin correlates with non-invasive hepatocellular carcinoma,absence of portal vein spread, and good prognosis. J Pathol 2001;193:95-101

Matsuda Y, Ichida T, Genda T, et al. Loss of p16 contributes to p27 equestration by cyclin D(1)-cyclin dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003; 9(9):3389-96

Matsumura T, Makino R, and Mitamura K. Frequent downregulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001; 7:594-599

Nanashima A, Yano H, Yamaguchi H, et al. Immunohistochemical analysis of tumor biological factors in hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection. J Gastroenterol 2004; 39(2):148-54

Nhieu JTV, Renard CA, Wei Y et al. Nuclear accumulation of mutated β-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999; 155:703-710

O’Connor DS, Schechner JS, Adida C et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156:393-8

Ohashi R, Gao C, Miyazaki M, et al. Enhanced expression of cyclin E and cyclin A in human hepatocellular carcinomas. Anticancer Res 2001; 21:657-662

Ouchi K, Sugawara T, Ono H, et al. Mitotic index is the best predictive factor for survival of patients with resected hepatocellular carcinoma. Dig Surg 2000; 17:42-48

Qin LX, Tang ZY, Ma ZC et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002; 8(3):459-63

Qin LX, Tang ZY. The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol 2002; 8:385-92

Sugo H, Takamori S, Kojima K et al. The significance of p53 mutations as an indicator of the biological behaviour of recurrent hepatocellular carcinomas. Surg Today 1999; 29:849-855

Sun HC, Tang ZY, Li XM et al. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol 1999; 125:419-26

Watanabe J, Kushihata F, Honda K, et al. Prognostic significance of Bcl-xLIto in human hepatocellular carcinoma. Surgery 2004; 135(6):604-12

Wong CM, Fan ST and Ng IOL. β-catenin mutation and overexpression in hepatocellular carcinoma. Clinocopathologic and prognostic significance. Cancer 2001, 92:136-145

Xu X, Yamamoto H, Sakon M, et al. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res 2003; 9(5):1764-72

Zheng Q, Tang ZY, Xue Q et al. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J Cancer Res Clin Oncol 2000; 126:641-646


L’ALGORITMO DELLA DIAGNOSI PRECOCE

AISF Commissione "Imaging e valutazione emodinamica nella diagnosi epatologica". Lesioni focali epatiche maligne. In: Imaging e valutazione emodinamina nella diagnostica epatologica, AISF (Ed); 2003, 46-9

Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48:251-9

Borzio M, Borzio F, Macchi R, Croce AM, Bruno S, Ferrari A, Servida E. The evaluation of fine-needle procedures for the diagnosis of focal liver lesions in cirrhosis. J Hepatol 1994; 20:117-21

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J for the EASL Panel of Experts on HCC. Clinical Management of Hepatocellular Carcinoma Conclusions of the Barcelona-2000 EASL Conference, Barcelona September 15-17, 2000. J Hepatol 2001; 35:421-30

Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R, Caralt T, Ayuso JR, Sole M, Sanchez M, Bru C, Bruix J; Barcelona Clinic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38:1034-42

Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B, Moutardier V, Farges O, Valla D. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001; 35: 254-8

Fracanzani AL, Burdick L, Borzio M, Roncalli M, Bonelli M, Borzio F, Maraschi A, Fiorelli G, Fargion S. Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology 2001; 34:1109-12

Kim SH, Lim HK, Lee WJ, Cho JM, Jang HJ. Needle tract implantation in hepatocellular carcinoma: frequency and CT finding after biopsy with a 19.5-gauge automated biopsy gun. Abdom Imaging 2000; 25:246-50

Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. In: Viruses and Liver Cancer: perspectives in medical virology; Tabor E (Ed). Elsevier, Amsterdam; 2002, 113-122

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. New Engl J Med 1996; 334:693-699

Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multiinstitutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1998; 28:604-608

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, de Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126:1005-14

Sheu JC, Sung JL, Chen DS, Yang PM, Lai MY, Lee CS Hsu HC, Chuang CN, Yang PC, Wang TH. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89:259-266

Takamori R, Wong LL, Dang C, Wong L. Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary? Liver Transplant 2000; 6:67-72

Takayama T, Makuuchi S, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, Kosuge T, Okada S, Takayasu K, Yamasaki S. Early hepatocellular carcinoma as an entity with high rate of surgical cure. Hepatology 1998; 28: 1241-1246


STADIAZIONE

Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E; EASL Panel of Experts on HCC. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421-30

Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C for the Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol 1999; 31:133-141

Cillo U, Bassanello M, Vitale A, Grigoletto F, Burra P, Fagiuoli S et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004; 40:124-131

Greene FL , Page DL , Fleming ID, Fritz AG, Balch CM, Haller DG et al. (eds) AJCC Cancer Staging Manual (6th edn). Springer, Chicago 2002; 131-144

Grieco A, Pompili M, Caminiti G et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54:411-418

Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T et al. Validation of a new prognostic system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 40:1396-1405

Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38:207-215

Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the LiverItalian Program staging system: s a study based on 926 patients. Cancer 2002; 4:1760-1769

Levy I, Sherman M, the Liver Cancer Study Group of the University of Toronto. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50:881-885

Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338

Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41:707-716

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918-928

Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M Increased Survival of Cirrhotic Patients With a Hepatocellular Carcinoma Detected During Surveillance. Gastroenterology 2004; 26:1005-1014

The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755

The Cancer of the Liver Italian Program (CLIP) Investigators. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31:840-845

Wildi S, Pestalozzi BC, McCormack L, Clavien PA. Critical evaluation of the different staging systems for hepatocellular carcinoma. Br J Surg 2004; 91:400-408